Millennium Management LLC Raises Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• Millennium Management LLC increased its ownership in BioNTech by 252.5%, acquiring an additional 390,360 shares, bringing its total to 544,970 shares worth approximately $49.6 million.
• BioNTech's stock dropped 8.7%, and the company's recent earnings report revealed a loss of ($1.60) per share, missing estimates but showing a 102.6% increase in revenue year-over-year.
• Wall Street analysts have a mixed outlook on BioNTech, with thirteen analysts$135.80.

Millennium Management LLC lifted its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 252.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 544,970 shares of the company's stock after purchasing an additional 390,360 shares during the quarter. Millennium Management LLC owned 0.23% of BioNTech worth $49,625,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Banque Cantonale Vaudoise purchased a new position in shares of BioNTech in the 1st quarter worth about $36,000. Banque Transatlantique SA purchased a new stake in BioNTech during the 1st quarter valued at about $80,000. Costello Asset Management INC purchased a new stake in BioNTech during the 1st quarter valued at about $91,000. Goodman Advisory Group LLC purchased a new stake in BioNTech during the 1st quarter valued at about $105,000. Finally, Probity Advisors Inc. boosted its holdings in BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after acquiring an additional 154 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Down 7.3%

Shares of NASDAQ:BNTX traded down $7.57 during trading on Friday, hitting $96.74. The stock had a trading volume of 5,152,187 shares, compared to its average volume of 961,438. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $131.49. The company has a market capitalization of $23.26 billion, a PE ratio of -60.46 and a beta of 1.39. The firm's fifty day moving average is $109.05 and its 200 day moving average is $104.08. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same period last year, the business earned ($3.36) EPS. The firm's quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BNTX shares. Bank of America increased their target price on BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. JPMorgan Chase & Co. lowered their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Finally, Morgan Stanley upped their price target on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $135.80.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.